Immunotherapy of Cholangiocarcinoma

Study Name
  Immunotherapy of cholangiocarcinoma
ClinicalTrials.gov Identifier (if applicable)
  https://clinicaltrials.gov/ct2/show/NCT03042182
Study Center
Institution Name
  Immunitor LLC
Institution Address
  25 peace Avenue
City
  Ulaanbaatar
State
  New York
Zip Code
  14400
Phone
  (301) 476-0930
Website
  http://www.immunitor.com
Study Contacts
Principal Investigator
  Aldar Bourinbaiar
P.I. Phone
  (301) 476-0930
P.I. Email
  immunitor@gmail.com
Study Coordinator
  Immunitor LLC
Study Coordinator Phone
  (917) 326-9508
Study Coordinator Email
  info@immunitor.com
List additional Study Coordinators (include phone number and email)
  Study will be conducted in Mongolia, but those who are interested to join can apply for exemption
OVERVIEW – in layman’s terms (150 words max)
  Earlier version of immunotherapy, which was designed for patients with hepatocellular carcinoma (HCC) has shown limited efficacy in patients with cholangiocarcinoma (CCA). The decline in levels of CA19.9 marker common in CCA correlated with tumor shrinkage.
Enrollment
  started – target 20-30 patients
Study Start Date
  02/18/2017
Estimated Completion Date
  02/18/2018
Purpose of the Study – in Layman’s Terms (use the “+” to add more list items)
 
  • Efficacy of immunotherapy in patients with cholangiocarcinoma
Inclusion Criteria – Patients Must:
 
  • have CA19.9 tumor marker above normal levels
Exclusion Criteria – Patients Must NOT:
 
  • those with negative or normal CA19.9 will be excluded
REQUIRED TESTS PRIOR TO BEGINNING STUDY TREATMENT – in layman’s terms
 
  • blood test to identify CA19.9 levels
POTENTIAL SIDE-EFFECTS – in layman’s terms
 
  • therapy has no side effects

Pin It on Pinterest